Log In
Print this Print this

BAY 1187982

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionAntibody-drug conjugate targeting keratinocyte growth factor (KGF) receptor (KGFR; FGFR2; CD332)
Molecular Target Keratinocyte growth factor (KGF) receptor (KGFR) (FGFR2) (CD332)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat FGFR2-positive solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today